What is the initiating dose of Campral (Acamprosate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Campral (Acamprosate) Initiating Dose

The standard initiating dose of Campral is 666 mg (two 333 mg tablets) taken three times daily, for a total daily dose of 1998 mg (approximately 2 grams per day). 1

Standard Dosing Protocol

  • Start with 666 mg three times daily immediately after the patient achieves abstinence following alcohol withdrawal 1
  • Dosing can be done without regard to meals, though taking it with meals may be preferred if the patient regularly eats three meals daily 1
  • Treatment should be initiated as soon as possible after the alcohol withdrawal period when abstinence has been achieved 1

Dose Modifications for Renal Impairment

Moderate renal impairment (creatinine clearance 30-50 mL/min):

  • Reduce starting dose to 333 mg three times daily (one tablet per dose) 1

Severe renal impairment (creatinine clearance ≤30 mL/min):

  • Acamprosate is contraindicated and should not be used 1

Clinical Context and Safety Profile

  • Acamprosate has no hepatic metabolism and is renally excreted, making it particularly advantageous in patients with liver disease 2
  • The American Association for the Study of Liver Diseases notes that acamprosate has no reported instances of hepatotoxicity, unlike naltrexone and disulfiram which undergo hepatic metabolism 2
  • Treatment must be part of a comprehensive psychosocial support program 1
  • The drug should be continued even if the patient relapses to alcohol use 1

Important Prescribing Considerations

  • Acamprosate is only effective in patients who have already achieved abstinence prior to starting treatment—it has not been shown to help patients who have not undergone detoxification 1
  • Steady-state plasma concentrations are reached after 5-7 days of treatment 3
  • The medication is not metabolized and is excreted unchanged in urine 3
  • Food decreases absorption, but this does not require dose adjustment 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical pharmacokinetics of acamprosate.

Clinical pharmacokinetics, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.